BLFS Biolife Solutions Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: BLFS

Price (delayed)

$27.06

Market cap

$1.32B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.06

Enterprise value

$1.31B

?
Relative Growth: Rel. Growth: 82
Relative Strength: Rel. Strength: 72
Relative Valuation: Rel. Valuation: 7
Relative Profitability: Rel. Profitability: 45

BioLife Solutions is a leading supplier of cell and gene therapy bioproduction products and services. Its products and services portfolio includes its proprietary CryoStor® freeze media, HypoThermosol® shipping and storage ...

Highlights
The EPS has surged by 74% year-on-year and by 33% since the previous quarter
BLFS's net income has surged by 72% year-on-year and by 36% since the previous quarter
BLFS's gross margin is down by 4.9% year-on-year
Sector: Healthcare
Industry: Medical Instruments & Supplies
Website: http://www.biolifesolutions.com
Peers: CE ENTA

Key stats

What are the main financial stats of BLFS

BLFS stock price

How has the Biolife Solutions stock price performed over time
Intraday
-0.7%
1 week
7.17%
1 month
28.31%
1 year
22.83%
YTD
11.91%
QTD
41.82%

Financial performance

How have Biolife Solutions's revenue and profit performed over time
Revenue
$99.77M
Gross profit
$63.83M
Operating income
-$15.36M
Net income
-$2.96M
Gross margin
64%
Net margin
-3%
The net margin has surged by 77% year-on-year and by 38% since the previous quarter
BLFS's net income has surged by 72% year-on-year and by 36% since the previous quarter
The company's revenue rose by 27% YoY and by 3.7% QoQ
The company's gross profit rose by 21% YoY and by 2.8% QoQ

Price vs fundamentals

How does BLFS's price correlate with its fundamentals

Growth

What is Biolife Solutions's growth rate over time

Valuation

What is Biolife Solutions stock price valuation
BLFS P/E details
P/E
N/A
P/B
3.51
P/S
13.14
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
13.17
The EPS has surged by 74% year-on-year and by 33% since the previous quarter
BLFS's price to book (P/B) is 26% higher than its 5-year quarterly average of 2.8 and 18% higher than its last 4 quarters average of 3.0
The equity has grown by 6% YoY
The company's revenue rose by 27% YoY and by 3.7% QoQ
The P/S is 13% higher than the last 4 quarters average of 11.7

Efficiency

How efficient is Biolife Solutions business performance
Biolife Solutions's return on assets has surged by 74% YoY and by 42% QoQ
The ROE has soared by 74% YoY and by 38% from the previous quarter
The ROIC has soared by 58% YoY and by 25% from the previous quarter
The return on sales has surged by 56% year-on-year and by 21% since the previous quarter

Dividends

What is BLFS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for BLFS.

Financial health

How did Biolife Solutions financials performed over time
BLFS's current ratio has surged by 54% year-on-year and by 23% since the previous quarter
BLFS's quick ratio is up by 46% year-on-year and by 22% since the previous quarter
The debt is 96% smaller than the equity
Biolife Solutions's debt to equity has plunged by 50% YoY and by 20% from the previous quarter
The debt has declined by 45% year-on-year and by 17% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.